|
 Gelesis100 achieved meaningful weight loss of 5 percent or more in
58 percent of adults in the study, meeting one of two clinical
targets, with almost twice as many adults losing 10 percent or more
of their body weight compared with those taking a placebo.
It noted, however, that the study did not meet the other target of a
3 percent average difference from the placebo.
"Given the demonstrated weight loss and safety profile, Gelesis
plans to discuss filing with regulatory authorities and, if they are
supportive, plans to file for approval," it said.
Gelesis100 is a capsule that contains small hydrogel particles that
hydrate to almost 100 times their original size in the stomach.
The particles are made from two naturally derived ingredients and
mix homogeneously with food in the body to reduce hunger, leading to
weight loss. Once in the large intestine, the particles release most
of the water, which is reabsorbed.
[to top of second column] |
Analysts at broker Liberum said this is not the perfect result for
PureTech, given one of the two primaries was missed.
"However, the proportion of patients losing 5 percent of body weight
was almost twice the target, and the safety profile looks so clean
from the top-line data that this would appear to deliver meaningful
risk/benefit," they said.
(Reporting by Paul Sandle; Editing by David Goodman)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
